ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,294.10
-0.42%
S&P ASX All Technology
3,845.90
-0.28%
Brent Oil
79.285
0.00%
US Dollar vs AUD
1.62608
-0.09%
Bitcoin
95,131.03
0.58%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Biogen Inc (BIIB)

  7. Biogen Inc (BIIB) News

BIIB

Biogen (BIIB)

Biogen Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BIIB
DateTimeSourceHeadlineSymbolCompany
11/01/202509:34Edgar (US Regulatory)Form SCHEDULE 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:BIIBBiogen Inc
08/01/202508:14Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
10/12/202408:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
10/12/202408:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
10/12/202402:33Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BIIBBiogen Inc
05/12/202410:31PR Newswire (US)"LEQEMBI®" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in MexicoNASDAQ:BIIBBiogen Inc
28/11/202411:31PR Newswire (US)"LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South KoreaNASDAQ:BIIBBiogen Inc
19/11/202417:00GlobeNewswire Inc.Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease ActivityNASDAQ:BIIBBiogen Inc
15/11/202405:29PR Newswire (US)Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's DiseaseNASDAQ:BIIBBiogen Inc
15/11/202403:23GlobeNewswire Inc.Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s DiseaseNASDAQ:BIIBBiogen Inc
08/11/202408:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
05/11/202408:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
31/10/202410:30GlobeNewswire Inc.Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) ConferenceNASDAQ:BIIBBiogen Inc
31/10/202407:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BIIBBiogen Inc
31/10/202407:31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BIIBBiogen Inc
30/10/202421:55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BIIBBiogen Inc
30/10/202421:37IH Market NewsUS Futures Rise as Tech Earnings Drive Market Optimism; Oil Prices Edge UpNASDAQ:BIIBBiogen Inc
30/10/202409:00GlobeNewswire Inc.Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological DiseasesNASDAQ:BIIBBiogen Inc
29/10/202423:00GlobeNewswire Inc.Biogen Appoints Daniel Quirk, MD, as Chief Medical OfficerNASDAQ:BIIBBiogen Inc
28/10/202423:30GlobeNewswire Inc.Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025NASDAQ:BIIBBiogen Inc
27/10/202411:15GlobeNewswire Inc.Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024NASDAQ:BIIBBiogen Inc
24/10/202422:30GlobeNewswire Inc.Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual ConferenceNASDAQ:BIIBBiogen Inc
22/10/202422:30GlobeNewswire Inc.Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024NASDAQ:BIIBBiogen Inc
09/10/202422:30GlobeNewswire Inc.Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant RecipientsNASDAQ:BIIBBiogen Inc
08/10/202422:30GlobeNewswire Inc.New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMANASDAQ:BIIBBiogen Inc
08/10/202410:08Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
24/09/202415:00GlobeNewswire Inc.UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024NASDAQ:BIIBBiogen Inc
12/09/202421:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BIIBBiogen Inc
12/09/202421:30GlobeNewswire Inc.Biogen Board Appoints Two New Independent DirectorsNASDAQ:BIIBBiogen Inc
05/09/202420:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
 Showing the most relevant articles for your search:NASDAQ:BIIB

Your Recent History

LSE
VX16
Morg.st.b.v 24
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads